Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Molnupiravir  COVID-19 treatment studies for Molnupiravir  C19 studies: Molnupiravir  Molnupiravir   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality 60% Improvement Relative Risk Death/hospitalization -6% primary Hospitalization -9% Transmission 3% Sustained recovery 22% Recovery time 19% First recovery 30% Recovery time (b) 26% Viral load, day 14 -13% Viral load, day 7 20% Viral load, day 5 17% c19early.org/m Butler et al. ISRCTN30448031 PANORAMIC Molnupiravir RCT EARLY Favors molnupiravir Favors control
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): preliminary analysis from the United Kingdom randomised, controlled open-label, platform adaptive trial
Butler et al., SSRN (Preprint), PANORAMIC, ISRCTN30448031
6 Oct 2022    Source   PDF   Share   Tweet
25,000 patient RCT in the UK, showing faster recovery but no significant difference in hospitalization/death or transmission. Improved recovery may in part be due to placebo effect in this open label trial with self-reported symptomatic data. Viral load initially declined more quickly, but was higher at 14 days.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer [Hadj Hassine, Swanstrom]. See [twitter.com] for analysis of a variant potentially created by molnupiravir.
risk of death, 60.1% lower, RR 0.40, p = 0.29, treatment 2 of 12,516 (0.0%), control 5 of 12,484 (0.0%), NNT 4154, day 28.
risk of death/hospitalization, 6.0% higher, RR 1.06, p = 0.34, treatment 103 of 12,516 (0.8%), control 96 of 12,484 (0.8%), odds ratio converted to relative risk, day 28, primary outcome.
risk of hospitalization, 9.4% higher, RR 1.09, p = 0.57, treatment 102 of 12,516 (0.8%), control 93 of 12,484 (0.7%), day 28.
risk of transmission, 2.6% lower, RR 0.97, p = 0.90, treatment 3,890 of 10,823 (35.9%), control 3,874 of 10,557 (36.7%), NNT 133, odds ratio converted to relative risk.
risk of no sustained recovery, 21.9% lower, RR 0.78, p < 0.001, treatment 3,874 of 12,432 (31.2%), control 4,847 of 12,151 (39.9%), NNT 11.
recovery time, 19.4% lower, relative time 0.81, p < 0.001, treatment 12,432, control 12,151, inverted to make RR<1 favor treatment, sustained recovery.
risk of no first recovery, 30.3% lower, RR 0.70, p < 0.001, treatment 2,691 of 12,432 (21.6%), control 3,775 of 12,151 (31.1%), NNT 11.
recovery time, 26.5% lower, relative time 0.74, p < 0.001, treatment 12,432, control 12,151, inverted to make RR<1 favor treatment, first recovery.
viral load, 12.9% higher, relative load 1.13, p = 0.006, treatment mean 2.72 (±1.33) n=203, control mean 2.41 (±1.05) n=241, all samples, day 14.
viral load, 20.4% lower, relative load 0.80, p = 0.004, treatment mean 3.86 (±1.4) n=35, control mean 4.85 (±1.45) n=40, all samples, day 7.
viral load, 17.1% lower, relative load 0.83, p < 0.001, treatment mean 4.88 (±1.51) n=238, control mean 5.89 (±1.41) n=280, all samples, day 5.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Butler et al., 6 Oct 2022, Randomized Controlled Trial, United Kingdom, preprint, 54 authors, trial ISRCTN30448031 (PANORAMIC).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit